Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC) jointly announced on 2/25/19 the dosing of the first South Korean patient at the Asan Medical Center in South Korea in the on-going global pivotal Phase 3 trial of Xynomic’s abexinostat combined with pazopanib as a first- or second-line therapy against renal cell carcinoma (RCC). According to US International Trade Administration, South Korea is the third largest pharmaceutical market in Asia and the 13th largest globally. Furthermore, Xynomic plans to roll out this multi-national trial, currently ongoing in the United States, in Europe and China in the first half of 2019.
Abexinostat is a new type of histone deacetylase (HDAC) inhibitor — a drug class that prevents genes from being silenced and has been used successfully in cancers originating in T-cells. Xynomic currently has three candidates in development – all intended to treat various forms of cancer.
In September of last year, Xynomic announced a merger with Bison Capital Acquisition Corporation. Under the terms of the merger, Xynomic will receive up to $450 million in Bison shares.